Unresolved issues in myocardial reperfusion injury

Cardiovascular Pathology

Volumn 19, Issue 1, 2010, Pages 29-35

  Buja, Louis Maximilian ^a,b,c   Weerasinghe, Priya ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Myocardial ischemic injury; Myocardial reperfusion injury

Indexed keywords

ADENOSINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR ANTAGONIST; CYCLOSPORIN; FIBRINOLYTIC AGENT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; KAI 9803; MAGNESIUM; NICORANDIL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POTASSIUM; PROTEIN INHIBITOR; PROTEIN KINASE C DELTA INHIBITOR; PROTEIN KINASE INHIBITOR; SODIUM PROTON EXCHANGE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; APOPTOSIS; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ELUTING STENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INDUCED HYPOTHERMIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION; STEM CELL TRANSPLANTATION;

CLINICAL TRIALS AS TOPIC; HUMANS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC;

EID: 70849100002     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2008.10.001     Document Type: Review

References (65)

1. Jennings R.B., Sommers H.M., Smyth G.A., Flack H.H., and Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 70 (1960) 68-78
2. Jennings R.B., and Reimer K.A. Lethal myocardial ischemic injury. Am J Pathol 102 (1981) 241-255
3. Buja L.M., and Willerson J.T. Abnormalities of volume regulation and membrane integrity in myocardial tissue slides after early ischemic injury in the dog: effects of mannitol, polyethylene glycol, and propranolol. Am J Pathol 103 (1981) 79-95
4. Buja L.M., Hagler H.K., and Willerson J.T. Altered calcium homeostasis in the pathogenesis of myocardial ischemic and hypoxic injury. Cell Calcium 9 (1988) 205-217
5. Reimer K.A., Lowe J.E., Rasmussen M.M., and Jennings R.B. The wave front phenomenon of ischemic cell death: I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56 (1977) 786-794
6. Reimer K.A., and Jennings R.B. The "wavefront phenomenon" of myocardial ischemic cell death: II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40 (1979) 633-644
7. Kloner R.A., Ganote C.E., and Jennings R.B. The no-reflow phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54 (1974) 1496-1508
8. Braunwald E., and Kloner R.A. Myocardial reperfusion: a double-edge sword?. J Clin Invest 76 (1985) 1713-1719
9. Braunwald E., and Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66 (1982) 1146-1149
10. Kloner R.A., Przyklenk K., and Patel B. Altered myocardial states: the stunned and hibernating myocardium. Am J Med 86 suppl 1A (1989) 14-21
11. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
12. Murry C.E., Richard V.J., Reimer K.A., and Jennings R.B. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66 (1990) 913-931
13. Murry C.E., Richard V.J., Jennings R.B., and Reimer K.A. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol 260 (1991) H796-H804
14. Anversa P., and Sonnenblick E.H. Ischemic cardiomyopathy: pathophysiologic mechanisms. Prog Cardiovasc Dis 33 (1990) 49-70
15. Reimer K.A., and Ideker R.E. Myocardial ischemia and infarction: anatomic and biochemical substrates for ischemic cell death and ventricular arrhythmias. Hum Pathol 18 (1987) 462-475
16. Reimer K.A., and Jennings R.B. Myocardial ischemia, hypoxia, and infarction. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., and Morgan H.E. (Eds). The Heart and Cardiovascular System: Scientific Foundations. 2nd ed. vol. II (1992), Raven Press, New York 1875-1973
17. Buja L.M., and Willerson J.T. The role of coronary artery lesions in ischemic heart disease: insights from recent clinicopathologic, coronary arteriographic, and experimental studies. Hum Pathol 18 (1987) 451-461
18. Burke A.P., and Virmani R. Pathophysiology of acute myocardial infarction. Med Clin N Am 91 (2007) 553-572
19. Buja L.M. Modulation of the myocardial response to ischemia. Lab Invest 78 (1998) 1345-1373
20. Buja L.M. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 14 (2005) 170-175
21. Willerson J.T., and Buja L.M. Myocardial reperfusion: biology, benefits and consequences. Dialogues Cardiovasc Med 11 (2006) 267-278
22. Gross G.J., and Auchampach J.A. Reperfusion injury: does it exist?. J Mol Cell Cardiol 42 (2007) 12-18
23. Yellon D.M., and Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 357 (2007) 1121-1135
24. Buja L.M., Eigenbrodt M.L., and Eigenbrodt E.H. Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch Pathol Lab Med 117 (1993) 1208-1214
25. Majno G., and Joris I. Apoptosis, oncosis and necrosis. An overview of cell death. Am J Pathol 146 (1995) 3-15
26. Buja L.M., and Entman M.L. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98 (1998) 1355-1357
27. Kostin S., Pool L., Elsässer A., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92 (2003) 715-724
28. Kostin S. Pathways of myocyte death: implications for development of clinical laboratory biomarkers. Adv Clin Chem 40 (2005) 37-98
29. Buja L.M., and Vela D. Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc Pathol (2008) [electronic publication ahead of print]
30. Takemura G., and Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med 10 (2006) 56-75
31. Garg S., Hofstra L., Reutelingsperger C., and Narula J. Apoptosis as a therapeutic target in acutely ischemic myocardium. Curr Opin Cardiol 18 (2003) 372-377
32. Jugdutt B.I., and Idikio H.A. Apoptosis and oncosis in acute coronary syndromes: assessment and implications. Mol Cell Biochem 270 (2005) 177-200
33. Foo R.S., Mani K., and Kitsis R.N. Death begets failure in the heart. J Clin Invest 115 (2005) 565-571
34. Hallock S., Tang S.-C., Buja L.M., Trump B.F., Liepins A., and Weerasinghe P. Aurintricarboxylic acid inhibits protein synthesis independent, sanguinarine-induced apoptosis and oncosis. Toxicol Pathol 35 (2007) 300-309
35. Nishida K., Yamaguchi O., and Otsu K. Crosstalk between autophagy and apoptosis in heart disease. Circ Res 103 (2008) 343-351
36. Kloner R.A., and Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: Part 1. Circulation 104 (2001) 2981-2989
37. Kloner R.A., and Jennings R.B. Consequences of brief ischemia stunning, preconditioning, and their clinical implications: Part 2. Circulation 104 (2001) 3158-3167
38. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
39. Downey J.M., Davis A.M., and Cohen M.V. Signalling pathways in ischemic preconditioning. Heart Fail Rev 12 (2007) 181-188
40. Cannon C.P., Gibson C.M., Lambrew C.T., et al. Relationship of symptom-onset-to balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283 (2000) 2941-2947
41. Williams S.C., Schmaltz S.P., Morton D.J., et al. Quality of care in U.S. hospitals as reflected by standardized measures 2002-2004. N Engl J Med 353 (2005) 255-264
42. Brodie B.R., Stuckey T.D., Wall T.C., et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 32 (1998) 1312-1319
43. Brodie B.R., Hansen C., Stuckey T.D., et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 47 (2006) 289-295
44. Brodie B.R., Stone G.W., Cox D.A., et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J 151 (2006) 1231-1238
45. Smalling R.W., Giesler G.M., Julapalli V.R., et al. Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention: results of the PATCAR Pilot Trial. J Am Coll Cardiol. 50 (2007) 1612-1614
46. De Luca G., Suryapranata H., and Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 50 (2008) 352-382
47. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the "no reflow" phenomenon. Circulation 93 (1996) 223-228
48. Stone G.W., Peterson M.A., Lansky A.J., et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 39 (2002) 591-597
49. Singh K.P., and Harrington R.A. Primary percutaneous coronary intervention in acute myocardial infarction. Med Clin N Am 91 (2007) 639-655
50. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
51. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
52. Pohlen M., Bunzemeier H., Husemann W., et al. Risk predictors for adverse outcomes after percutaneous coronary interventions and their related costs. Clin Res Cardiol (2008) [electronic publication ahead of print]
53. Anderson H.V. Drug-eluting stents; life insurance with a better death benefit. J Am Coll Cardiol 51 (2008) 2025-2027
54. Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 46 (1995) 455-466
55. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 108 (2003) 1395-1403
56. Mann D.L., and Bristow M.R. Mechanisms and models of heart failure. The biomechanical model and beyond. Circulation 111 (2005) 2837-2849
57. Kloner R.A., and Hwang H. New insights into the open artery hypothesis. Circ Res 103 (2008) 1-3
58. Nakagawa M., Takemura G., Kanamori H., et al. Mechanisms by which late coronary reperfusion mitigates postinfarction cardiac remodeling. Circ Res 103 (2008) 98-106
59. Piot C., Croisille P., Staat P., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008) 478-481
60. Buja L.M., and Willerson J.T. Relationship of ischemic heart disease to sudden death. J Forensic Sci 36 (1991) 25-33
61. Huikuri H.V., Castellanos A., and Myerberg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
62. Franz W.-M., Muller O.J., and Katus H.A. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358 (2001) 1627-1637
63. McMurray J.J., and Pfeffer M.A. Heart failure. Lancet 365 (2005) 1877-1889
64. Laflamme M.A., Zbinden S., Epstein S.E., and Murry C.E. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol Mech Dis 2 (2007) 307-339
65. Vela D., and Buja L.M. Quest for the cardiovascular holy grail: mammalian myocardial regeneration. Cardiovasc Pathol 17 (2008) 1-5